Publications (2)1.95 Total impact
Article: Preoperative growth inhibition of human gastric adenocarcinoma treated with a combination of celecoxib and octreotide.[show abstract] [hide abstract]
ABSTRACT: To gain insight into the histopathological responses and molecular targets in the inhibition of growth of human gastric cancer treated with celecoxib (a cyclooxygenase [COX]-2 inhibitor) combined with octreotide. Seventy five patients with gastric cancer undergoing curative gastrectomy or extended resection were randomly divided into 3 groups. The apoptosis of tumor cells was measured by terminal deoxynucleotide transferase-mediated dUTP nick endlabeling (TUNEL) assay. Gastric cancer microvessel density (MVD) and the expression of COX-2 were evaluated by immunohistochemical staining. The expression of somatostatin receptor (SSTR)-2 was detected with the biomolecular interaction analysis system. The transcription of non-steroidal anti-inflammatory drug-activated gene (NAG)-1 was measured by RT-PCR. Compared with the control and celecoxib groups, more necrosis in the combination group was observed. The apoptotic rate in the combination group (7.06%+/-0.67%) was significantly higher than that in the control group (6.23%+/-1.29%, P<0.05). The MVD decreased considerably in the combination group. The upregulation of NAG-1 was displayed both in the celecoxib and combination groups. The positive rate of SSTR-2 in gastric cancers treated with celecoxib (48%) was significantly higher than that of control group (12%) after surgery (P<0.05). Celecoxib combined with octreotide significantly promoted necrosis in gastric adenocarcinoma through the induction of apoptosis and the reduction of MVD. NAG-1 and SSTR-2 might be the molecular targets for celecoxib or octreotide.Acta Pharmacologica Sinica 11/2007; 28(11):1842-50. · 1.95 Impact Factor
Article: [The inhibitive effects of celecoxib combined with octreotide on the metastasis of human gastric cancer in vivo].[show abstract] [hide abstract]
ABSTRACT: To investigated if cyclooxygenase-2 (COX-2) inhibitor celecoxib in combination with somatostatin (SST) analog octreotide is able to inhibit the metastasis of human gastric cancer (GC) in vivo. Seventy five patients with GC were randomly divided into 3 equal groups: control group, taking no anti-tumor medicine before GC resection; celecoxib group, receiving celecoxib orally 200 mg/d for 7 days before surgery; and combination group, receiving celecoxib orally 200 mg/d and octreotide 100 microg injected subcutaneously for 7 days before operation. The resected specimens were studied for the expression of epithelial cadherin (E-Cad) and matrix metalloproteinase (MMP) by using immunohistochemical staining. MMP-2 and MMP-9 were also quantified with Western blotting. The GC cells from the resected gastric cancer specimens were isolated by immunomagnetic separation. Modified Boyden chamber membrane invasion culture system coated with Matrigel was used to observe the migration and invasion of the GC cells. The abnormal staining rates of E-Cad of GC tissue in the combination group and the celecoxib group were 28.0% and 44.0%, significantly lower than that in the control group (56.0%, both P < 0.05). The grey level of MMP-2 and MMP-9 in the combination and celecoxib groups were (99 +/- 20, 89 +/- 13) and (260 +/- 15, 180 +/- 13) respectively, both significantly lower than that of the control group [(314 +/- 11, 241 +/- 12), P < 0.05]. The number of GC cells that penetrated the membrane was (2.75 +/- 0.58)/10(3) cells in the combination group, (2.29 +/- 0.58)/10(3) cells, the migration rate of the combination group was lower by 38% compared with that of the control group (F = 6.44, P < 0.05). The metastasis of human gastric carcinoma cells may be inhibited by the combinative treatment of celecoxib and octreotide.Zhonghua yi xue za zhi 12/2006; 86(46):3255-9.